Oxford Biomedica signs expanded CAR‑T supply pact with Bristol Myers Squibb
Gene and cell therapy company Oxford Biomedica Plc said on Wednesday that it has expanded its strategic partnership with Bristol Myers Squibb, inking a new commercial supply agreement for the manufacture and supply of lentiviral vectors for BMS' CAR-T programmes.
Under the new agreement, Oxford Biomedica was expected to commence commercial manufacturing at its facilities in Oxford and Durham, North Carolina in 2026, subject to regulatory approval.
Oxford Biomedica expects the supply agreement to generate "meaningful multi-year revenue" and support existing medium-term financial guidance. It also noted that the expanded partnership builds on the pair's existing relationship, which was originally announced in March 2020.
As of 0815 GMT, Oxford Biomedica shares were up 1.83% at 833p.
Reporting by Iain Gilbert at Sharecast.com
Disclaimer & Declaration of Interest
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.
